|
**Overview**: Fatty Liver Index Panel**Introduction**: The Fatty Liver Index Panel is a diagnostic tool designed to assess fatty liver risk using serum samples. In India, non-alcoholic fatty liver disease (NAFLD) affects ~25-30 percent of adults (higher in urban/metabolic syndrome populations, ~40-50 percent in diabetics/obese), with fatty liver index (FLI) calculated from AST, ALT, GGT, and BMI as a validated noninvasive marker for steatosis detection. High burden from underdiagnosis in rural/low-SES groups due to asymptomatic nature, limited ultrasound access, delayed lifestyle intervention leading to progression to NASH, fibrosis, cirrhosis, or HCC. Per hepatology practices aligned with ICMR and Indian National Association for Study of the Liver guidelines, the test employs spectrophotometry for liver enzymes and FLI calculation over 1-2 days with high accuracy, valuable for community/metabolic screening without imaging. This diagnostic falls under liver disease screening and targets patients with obesity, diabetes, or elevated ALT, addressing accurate risk stratification to guide diet/exercise or further evaluation. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise noninvasive assessment and reducing NAFLD-related complications. Its serum-based approach ensures reliable performance in India's diverse laboratory settings.**Other Names**: Fatty Liver Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: FLI validated as surrogate; in India, adopted in metabolic clinics.**Purpose**: The test assesses 4 parameters including AST to calculate FLI, guide fatty liver risk evaluation, stratify steatosis probability, inform management.**Test Parameters**: 1. AST, 2. ALT, 3. GGT, 4. BMI.**Pretest Condition**: Fasting 10-12 hours recommended; patients should report weight gain, fatigue, or risk factors.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on BMI, alcohol use, diabetes, family liver disease.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated fatty liver including cirrhosis, benefits of early risk assessment, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and calculate FLI within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or BMI inaccuracy can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High FLI indicates increased steatosis risk, necessitating specialist input. Low FLI may require follow-up in high-risk.**Specialist Consultation**: Hepatologists should be consulted for management.**Additional Supporting Tests**: Ultrasound, FibroScan for confirmation.**Test Limitations**: Surrogate marker only; comprehensive approach required.**References**: Indian Journal of Gastroenterology 2024, NAFLD Studies India 2023. |
